In fibromyalgia patients, when is bupropion (Wellbutrin) indicated, what is the recommended dosing schedule, what are its contraindications, and what benefits can be expected?

Bupropion (Wellbutrin) in Fibromyalgia

Bupropion is not a first-line or recommended treatment for fibromyalgia based on current evidence. The most recent and highest-quality guideline for fibromyalgia management (2022 VA/DoD) found insufficient evidence to recommend bupropion for this condition 1.

Current Evidence Status

The 2022 VA/DoD Clinical Practice Guideline for Chronic Multisymptom Illness (which includes fibromyalgia) does not include bupropion among its recommendations 1. The guideline specifically states there is insufficient evidence to recommend for or against mirtazapine, selective serotonin reuptake inhibitors (SSRIs), or amitriptyline for fibromyalgia pain 1. Bupropion is notably absent from even this "insufficient evidence" category.

The 2017 EULAR guidelines for fibromyalgia management similarly do not include bupropion in their recommendations, focusing instead on amitriptyline, duloxetine, milnacipran, pregabalin, and tramadol as pharmacological options 2.

Limited Research Evidence

While older research studies from 2000-2001 showed bupropion SR (150-300 mg daily) had some efficacy for neuropathic pain specifically 3, 4, these were:

• Small studies (22-41 patients)
• Focused on neuropathic pain, not fibromyalgia specifically
• Open-label or single-center designs
• Not replicated in larger, multi-center trials

The mechanism was thought to involve norepinephrine reuptake blockade 4, but this has not translated into established efficacy for fibromyalgia.

Recommended First-Line Treatments Instead

For fibromyalgia pain and functional improvement, use these evidence-based options:

Pharmacological (in order of recommendation strength):

1. Serotonin-norepinephrine reuptake inhibitors (SNRIs): Duloxetine or milnacipran 1, 2
2. Pregabalin for pain 1, 2
3. Amitriptyline at low doses 2
4. Tramadol (weak recommendation) 2

Non-Pharmacological (strongly recommended):

1. Aerobic and strengthening exercise (strong recommendation) 2
2. Cognitive-behavioral therapy 1, 2
3. Mindfulness-based therapies 1, 2
4. Yoga or tai chi 1
5. Manual acupuncture 1

If Bupropion Were Considered (Off-Label)

Should a clinician consider bupropion off-label despite lack of guideline support, the dosing from neuropathic pain studies and FDA labeling would be:

Dosing schedule:

• Days 1-3: 150 mg orally once daily in the morning
• Day 4 onward: 150 mg orally twice daily if tolerated
• Maximum: 300 mg per day 5, 6

Contraindications (critical):

• Seizure disorders or conditions that lower seizure threshold (stroke, brain metastases, eating disorders, abrupt alcohol/benzodiazepine withdrawal) 5, 6
• MAO inhibitor use (within 14 days) 6
• Closed-angle glaucoma 5
• Concurrent tamoxifen use 5

Common adverse effects:

• Insomnia (take second dose early in day, not evening)
• Dry mouth
• Tremor
• Headache
• Gastrointestinal upset 3, 4

Clinical Bottom Line

Do not use bupropion for fibromyalgia. Instead, initiate treatment with:

1. Patient education about fibromyalgia
2. Aerobic exercise program
3. Trial of duloxetine (30 mg daily for 1 week, then 60 mg daily) OR pregabalin (50 mg three times daily, titrate to 100 mg three times daily)
4. Add cognitive-behavioral therapy or mindfulness-based therapy

This approach is supported by the highest quality, most recent guidelines and prioritizes both efficacy and safety for improving pain, function, and quality of life in fibromyalgia patients 1, 2.